Entry |
|
Name |
Zoledronic acid (USAN); Zoledronic acid hydrate (JAN); Zometa (TN); Reclast (TN) |
Product |
|
Generic |
ZOLEDRONIC ACID (Accord Healthcare), ZOLEDRONIC ACID (Akorn), ZOLEDRONIC ACID (Apotex Corp), ZOLEDRONIC ACID (Athenex Pharmaceutical Division), ZOLEDRONIC ACID (Athenex Pharmaceutical Division), ZOLEDRONIC ACID (AuroMedics Pharma LLC), ZOLEDRONIC ACID (AuroMedics Pharma LLC), ZOLEDRONIC ACID (BPI Labs), ZOLEDRONIC ACID (BluePoint Laboratories), ZOLEDRONIC ACID (BluePoint Laboratories), ZOLEDRONIC ACID (BluePoint Laboratories), ZOLEDRONIC ACID (Breckenridge Pharmaceutical), ZOLEDRONIC ACID (Breckenridge Pharmaceutical), ZOLEDRONIC ACID (Dr. Reddy's Laboratories), ZOLEDRONIC ACID (Dr. Reddy's Laboratories), ZOLEDRONIC ACID (Dr. Reddy's Laboratories Limited), ZOLEDRONIC ACID (Dr.Reddy's Laboratories), ZOLEDRONIC ACID (Dr.Reddy's Laboratories), ZOLEDRONIC ACID (Fresenius Kabi USA), ZOLEDRONIC ACID (Fresenius Kabi USA), ZOLEDRONIC ACID (Gland Pharma Limited), ZOLEDRONIC ACID (Gland Pharma Limited), ZOLEDRONIC ACID (Gland Pharma Limited), ZOLEDRONIC ACID (Gland Pharma Limited), ZOLEDRONIC ACID (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals), ZOLEDRONIC ACID (Hospira), ZOLEDRONIC ACID (Hospira), ZOLEDRONIC ACID (Hospira), ZOLEDRONIC ACID (Ingenus Pharmaceuticals), ZOLEDRONIC ACID (Mylan Institutional LLC), ZOLEDRONIC ACID (Mylan Institutional LLC), ZOLEDRONIC ACID (Mylan Institutional LLC), ZOLEDRONIC ACID (Mylan Institutional LLC), ZOLEDRONIC ACID (Northstar RxLLC), ZOLEDRONIC ACID (Sagent Pharmaceuticals), ZOLEDRONIC ACID (Sagent Pharmaceuticals), ZOLEDRONIC ACID (West-Ward Pharmaceuticals Corp) |
Formula |
C5H10N2O7P2. H2O
|
Exact mass |
290.0069
|
Mol weight |
290.1049
|
Structure |

|
Simcomp |
|
Class |
|
Remark |
Therapeutic category: | 3999 |
Product (DG00787): | D01968<JP/US> |
|
Efficacy |
Antihypercalcemia, Antiresorptive, Farnesylpyrophosphate synthetase inhibitor |
Disease |
Osteoporosis [DS: H01593] Glucocorticoid-induced osteoporosis [DS: H01709] Paget's disease of bone [DS: H00437] Multiple myeloma [DS: H00010] |
Comment |
Bisphosphonate
|
Target |
|
Pathway |
hsa00900 | Terpenoid backbone biosynthesis |
|
Interaction |
|
Structure map |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BA Bisphosphonates
M05BA08 Zoledronic acid
D01968 Zoledronic acid (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Treatment Adjuncts
Zoledronic Acid
D01968 Zoledronic acid (USAN)
Metabolic Bone Disease Agents
Bisphosphonates
Zoledronic Acid
D01968 Zoledronic acid (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D01968 Zoledronic acid (USAN); Zoledronic acid hydrate (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Alkyl/Aryl transferases
FDPS
D01968 Zoledronic acid (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01968
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01968
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01968
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01968
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 17
1 O0 O 28.8400 -25.1300
2 C1d C 23.3100 -23.8000
3 P1b P 24.5700 -24.4300
4 P1b P 22.1200 -24.4300
5 C1b C 23.3100 -22.4000
6 O1c O 20.9300 -23.8000
7 O1c O 22.1200 -25.8300
8 O1c O 20.5800 -25.4100
9 O1c O 25.6900 -23.8000
10 O1c O 24.5700 -25.8300
11 O1c O 25.6900 -25.1300
12 O1a O 23.3100 -25.2000
13 N4y N 24.5000 -21.7000
14 C8x C 25.8300 -22.1200
15 N5x N 26.6700 -21.0000
16 C8x C 25.8300 -19.8800
17 C8x C 24.5000 -20.3000
BOND 16
1 2 3 1
2 2 4 1
3 2 5 1
4 4 6 2
5 4 7 1
6 4 8 1
7 3 9 2
8 3 10 1
9 3 11 1
10 2 12 1
11 5 13 1
12 13 14 1
13 14 15 2
14 15 16 1
15 16 17 2
16 13 17 1
|
|